Maintain Buy with TP of Rs 6900.
Building on OTC now with acquisition of NRT brands.
Under-invested brand with multiple levers in place.
Acquisition is in line with the stated strategy of investing in sustainable growth drivers augmenting the OTC business.
See the business replacing the gRevlimid hole over time.
Deal could be EPS neutral in year-2 assuming gradual growth and 25% margins.
Comments
Post a Comment